Halozyme Therapeutics, INC Form 4 insider transactions

Halozyme Therapeutics Director James Paul Lang was granted 889 restricted stock units and options to purchase 1,342 shares of common stock as part of the company's director compensation program.

HALOZYME THERAPEUTICS Director Bernadette Connaughton sold 2,000 shares of common stock for $70.25 per share, executed under a pre-arranged 10b5-1 trading plan.

Halozyme Therapeutics' SVP, Chief Legal Officer, Mark Howard Snyder, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Halozyme Therapeutics' COO, Cortney Caudill, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.

Halozyme Therapeutics' President and CEO, Helen Torley, was granted 165,522 performance-based Restricted Stock Units tied to specific stock price targets over a four-year period.

Halozyme Therapeutics Director Bernadette Connaughton sold 829 shares of common stock for $71.60 per share under a pre-arranged 10b5-1 trading plan.

Halozyme Therapeutics CEO Helen Torley reported a gift of 25,000 shares to charity and the exercise and immediate sale of 16,569 stock options.

Halozyme Therapeutics' President and CEO, Helen Torley, exercised and immediately sold 60,000 shares of common stock over three days in November 2025, pursuant to a Rule 10b5-1 trading plan.

HALOZYME THERAPEUTICS Director Bernadette Connaughton sold 2,000 shares of common stock for $68.48 per share, reducing her direct beneficial ownership to 42,952 shares.

Cortney Caudill, SVP and Chief Operating Officer of Halozyme Therapeutics, was granted 9,031 stock options and 3,625 restricted stock units on October 3, 2025.

Halozyme Therapeutics CEO Helen Torley executed pre-planned transactions in early October 2025, exercising stock options and subsequently selling 60,000 common shares.

A director at Halozyme Therapeutics, Bernadette Connaughton, sold 2,000 shares of common stock for approximately $150,481 through a pre-arranged trading plan.

Halozyme Therapeutics' SVP and Chief Financial Officer, Nicole LaBrosse, sold 2,227 shares of common stock through a pre-arranged 10b5-1 trading plan.

Halozyme Therapeutics' CFO, Nicole LaBrosse, filed a Form 4 detailing planned exercises of stock options and subsequent sales of common stock on September 10, 2025, under a Rule 10b5-1 trading plan.

Halozyme Therapeutics' President and CEO, Helen Torley, exercised stock options and subsequently sold common stock in early September 2025, as part of a pre-arranged 10b5-1 trading plan.

A director at Halozyme Therapeutics sold common stock totaling 4,000 shares on September 2, 2025, under a pre-arranged trading plan.

Halozyme Therapeutics CEO Helen Torley exercised stock options and sold shares totaling 60,000 units over three days in August 2025, realizing significant gains.

Halozyme Therapeutics' President and CEO, Helen Torley, reported the exercise of stock options and subsequent sale of common shares totaling approximately $3.39 million over three days in July 2025, all conducted under a pre-established Rule 10b5-1 trading plan.

Halozyme Therapeutics, Inc. President and CEO Helen Torley completed a series of pre-arranged option exercises and subsequent stock sales totaling 60,000 shares in late June 2025, as detailed in a recent SEC Form 4 filing.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, Inc. (HALO), reported the vesting of restricted stock units and a subsequent disposition of shares for tax withholding purposes.

Akiko Moni Miyashita, a director at Halozyme Therapeutics, reports the acquisition of restricted stock units and stock options as part of the company's director compensation program.

Director Jeffrey William Henderson acquired shares and options in Halozyme Therapeutics, Inc. on May 1, 2025, according to a Form 4 filing.

Director Matthew L. Posard reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics, Inc.

Director Krishnan Mahesh reports acquisition of restricted stock units and stock options in Halozyme Therapeutics.

Director Barbara Gayle Duncan reports acquisition of stock and option grants from Halozyme Therapeutics.

Director Bernadette Connaughton reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics under the company's director compensation program.

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on April 28, 2025, under a pre-arranged trading plan.

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 503 shares of common stock at $64.05 per share on April 1, 2025, under a pre-arranged trading plan.

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged trading plan.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, sold shares of common stock between February 25 and February 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.